Image For Representation

Cipla to sell anti-viral drug remdesivir as Cipremi in India

Mumbai: Drug maker Cipla Limited on Sunday announced the launch of experimental anti-viral drug remdesivir under its brand name Cipremi. Remdesivir is the only US FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, US drug maker Gilead Sciences extended a voluntary non-exclusive […]

Image For Representational Purpose Only (Pixabay)

Bangladesh based Beximco Pharmaceuticals becomes 1st company in world to produce generic version of Remdesivir

Dhaka: Bangladesh-based Beximco Pharmaceuticals has become the world’s first company to produce a generic version of the antiviral drug remdesivir, originally developed by US-based Gilead Sciences, it was reported on Friday. Remdesivir was originally designed as an Ebola treatment, the BBC reported. It works by attacking an enzyme that a virus needs in order to replicate […]

Picture For Representation

US drug-maker Gilead Sciences inks pact with 3 Indian drugmakers to produce, sell Remdesivir

New Delhi: US drug-maker Gilead Sciences has signed non-exclusive voluntary licensing agreements with three Indian pharmaceutical companies — Mumbai-headquartered Cipla, Hyderabad-based Hetero Labs and Noida-based Jubilant Life Sciences — who will manufacture and sell the anti-viral drug to treat severe COVID-19 patients. Gilead’s Remdesivir has received emergency use authorisation (EUA) from the US Food and Drug […]